Rigel Pharmaceuticals | RIGL - Ebit


Rigel Pharmaceuticals reported $447K in EBIT for its fiscal quarter ending in June of 2024.





Ebit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.83B 130M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD -12.1M 32.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025